Novo Nordisk reports semaglutide 2.4mg cuts liver enzymes, weight and blood sugar in real-world MASH study, beating resmetirom on AST

Novo Nordisk reports that semaglutide 2.4mg (Wegovy) was associated with reductions in liver enzymes, weight and blood sugar in adults with MASH in a real-world study, with significantly greater reductions than resmetirom in AST and some cardiometabolic measures.

Detected & updated continuously · Source: Nebula